Get the Stockscreener App
113.17
2.38%
2.63
Pre-market:
114.40
1.23
+1.09%
Overview
News
Price History
Option Chain
Financials
Why RVTY Down?
Discussions
Forecast
Stock Split
Dividend History
Revvity Inc stock is traded at $113.17, with a volume of 1.50M.
It is up +2.38% in the last 24 hours and up +13.28% over the past month.
Revvity is a global life sciences and diagnostics company formed in 2023 following the rebranding of PerkinElmer. The company operates in two segments: life sciences, which provides reagents and instruments for biopharma and academic research, and signals software, and diagnostics, which offers tools in immunodiagnostics and newborn and reproductive health. Revvity's products and services are sold worldwide, with major markets in the US, Europe, and China.
See More
Previous Close:
$110.54
Open:
$113.2
24h Volume:
1.50M
Relative Volume:
1.02
Market Cap:
$12.63B
Revenue:
$2.90B
Net Income/Loss:
$239.11M
P/E Ratio:
53.64
EPS:
2.1097
Net Cash Flow:
$492.62M
1W Performance:
+1.32%
1M Performance:
+13.28%
6M Performance:
-3.05%
1Y Performance:
+13.80%
1-Day Range:
$110.91
$116.00
1-Week Range:
$102.36
$116.00
52-Week Range:
$81.22
$118.30
Revvity Inc Stock (RVTY) Company Profile
Name
Revvity Inc
Sector
Industry
Phone
781-663-6900
Address
77 4TH AVENUE, WALTHAM
Compare RVTY vs TMO, DHR, IDXX, A, NTRA
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RVTY
Revvity Inc
|
113.17 | 12.63B | 2.90B | 239.11M | 492.62M | 2.1097 |
TMO
Thermo Fisher Scientific Inc
|
572.32 | 212.69B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
192.50 | 135.32B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
539.37 | 42.55B | 4.45B | 1.10B | 1.06B | 13.59 |
A
Agilent Technologies Inc
|
139.74 | 39.47B | 7.23B | 1.41B | 1.09B | 4.979 |
NTRA
Natera Inc
|
264.69 | 37.91B | 2.50B | -226.32M | 71.51M | -1.6412 |
Revvity Inc Stock (RVTY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-14-26 | Downgrade | Barclays | Overweight → Equal Weight |
| Dec-15-25 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-09-25 | Initiated | Goldman | Neutral |
| Oct-16-25 | Initiated | Guggenheim | Neutral |
| May-01-25 | Upgrade | UBS | Neutral → Buy |
| Jan-10-25 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Dec-13-24 | Upgrade | BofA Securities | Neutral → Buy |
| Oct-15-24 | Upgrade | Barclays | Equal Weight → Overweight |
| Aug-28-24 | Initiated | Wells Fargo | Equal Weight |
| Jul-08-24 | Initiated | Leerink Partners | Outperform |
| Jun-03-24 | Resumed | Jefferies | Hold |
| Jan-16-24 | Downgrade | UBS | Buy → Neutral |
| Jan-04-24 | Upgrade | Evercore ISI | In-line → Outperform |
| Dec-19-23 | Initiated | Wells Fargo | Equal Weight |
| Dec-13-23 | Initiated | Wolfe Research | Peer Perform |
| Sep-28-23 | Initiated | Bernstein | Outperform |
| Jul-19-23 | Initiated | Raymond James | Outperform |
| May-23-23 | Resumed | Goldman | Buy |
View All
Revvity Inc Stock (RVTY) Latest News
Revvity Inc. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch
Revvity Announces Development of High-Throughput T-SPOT.TB Automated Platform for Clinical Labs - FinancialContent
Revvity, Inc. (RVTY) stock price, news, quote and history - Yahoo Finance UK
Revvity, Inc. (RVTY) Stock Price, News, Quote & History - Yahoo! Finance Canada
Revvity, Inc. (RVTY) Q3 2024 Earnings ReportResults, Call & Slides - TipRanks
Insider Sell Alert: Anita Gonzales Sells Shares of Revvity Inc (RVTY) - GuruFocus
How Revvity’s (RVTY) Startup Software Push and ESG Disclosures Reframe Its Competitive Positioning - simplywall.st
Revvity to Launch Signals for Startups for Emerging Biotech Companies - The Globe and Mail
Revvity Inc. Stock Slides 3.4%, Underperforms Peers - webull.com
Revvity stock holds steady as Q1 2026 growth and margin expansion underpin valuation - Ad-hoc-news.de
Precision Trading with Revvity Inc. (RVTY) Risk Zones - Stock Traders Daily
Revvity Inc (RVTY) Stock Down 3.4% -- Now Undervalued? GF Score: 72/100 - GuruFocus
Revvity Inc. stock underperforms Monday when compared to competitors - MarketWatch
Revvity Launches “Signals for Startups” to Help Emerging Biotechs Build Scalable Digital Foundations from Day One - 01net
RVTY (RVTY) investor files notice to sell 85 common shares - Stock Titan
Revvity (NYSE: RVTY) removes 1.875% notes due 2026 from NYSE listing - Stock Titan
Revvity launches “Signals for Startups” to give emerging biotechs an enterprise-grade digital edge - Indian Chemical News
Revvity Releases 2026 Impact Report Advancing Transparency with Initial Scope 3 Emissions Disclosure - Lelezard
Revvity stock trades steadily as recent earnings highlight margin focus - Ad-hoc-news.de
PKI5144059 Bond Coupon Profile — Rate & Payments - TradingView
Revvity (NYSE: RVTY) VP Gonzales sells 85 shares under 10b5-1 plan - Stock Titan
PKI5144059 Bond Profile — Key Metrics - TradingView
XS1405780617 Bond Coupon Profile — Rate & Payments - TradingView
XS1405780617 Bond Risk Profile - TradingView
PKI5255604 Bond Risk Profile - TradingView
XS1405780617 Bond Profile — Key Metrics - TradingView
Revvity stock trades steady as genomics and diagnostics revenue underpins valuation - Ad-hoc-news.de
Revvity, Inc. (PKN) Q1 2024 Earnings ReportResults, Call & Slides - TipRanks
Revvity, Inc. (PKN) Q3 2024 Earnings ReportResults, Call & Slides - TipRanks
Revvity Inc. stock underperforms Friday when compared to competitors - MarketWatch
PKI5255604 Bond Profile — Key Metrics - TradingView
PKI5255604 Bond Coupon Profile — Rate & Payments - TradingView
Revvity stock trades steadily as recent earnings highlight growth and margin pressure - Ad-hoc-news.de
Revvity Inc. stock outperforms competitors on strong trading day - MSN
Revvity (RVTY) Q4 2025 earnings summary - Quartr
TD Cowen Adjusts Price Target on Revvity to $130 From $120, Maintains Buy Rating - marketscreener.com
REVVITY INC : TD COWEN RAISES TARGET PRICE TO $130 FROM $120 - Moomoo
TD Cowen Maintains Revvity(RVTY.US) With Buy Rating, Raises Target Price to $130 - Moomoo
Revvity (RVTY) Investor Day 2024 Summary - Quartr
Revvity (RVTY) TD Cowen 46th Annual Health Care Conference Summary - Quartr
Revvity (RVTY) Citi Annual Global Healthcare Conference 2025 Summary - Quartr
PKI4882935 Bond Risk Profile - TradingView
A184AM Bond Risk Profile - TradingView
A184AM Bond Coupon Profile — Rate & Payments - TradingView
S&P Global upgrades Revvity outlook on leverage improvement By Investing.com - Investing.com Nigeria
A184AM Bond Profile — Key Metrics - TradingView
PKI5255603 Bond Profile — Key Metrics - TradingView
S&P Global upgrades Revvity outlook on leverage improvement - Investing.com
Revvity: Overvalued On Sentiment (NYSE:RVTY) - Seeking Alpha
The path to AI federated learning for drug discovery - Scientific Computing World
Baird Adjusts Price Target on Revvity to $128 From $117, Maintains Outperform Rating - marketscreener.com
Revvity Inc Stock (RVTY) Financials Data
Revenue
Net Income
Cash Flow
EPS
8.61%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):